Health Boards
More good news for Cosentyx as Canada follow USA, Europe and Japan and gives approval for it's use in the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Source: novartis.ca
Quote:
Novartis announced today that Health Canada has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Offering a new treatment option for Canadians living with plaque psoriasis, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A.
"An unmet need exists in the treatment of moderate-to-severe plaque psoriasis in achieving clear to almost clear skin and not all treatments are effective in all patients." said Dr. Richard Langley, Professor in Dermatology of Medicine, and Director of Dermatology Research at Dalhousie University in Halifax, Nova Scotia. "Achieving clear skin is the ultimate treatment goal for patients with psoriasis; 50% of psoriasis patients are not content with current therapies. The approval of Cosentyx, a therapy targeting IL-17A for moderate-to-severe plaque psoriasis, offers a new treatment option for physicians in treating this condition."
"About 2% of Canadians are estimated to be diagnosed with psoriasis, and nearly half of them are dissatisfied with their current therapies, including biologic treatments, demonstrating a high unmet need for patients," said Tim Maloney, President of Novartis Pharmaceuticals Canada Inc. "We are excited about the Health Canada approval of Cosentyx and the potential opportunity to offer a new treatment option to these people."
Source: novartis.ca